Visiting Dana-Farber? See our prescreening and mask requirements.
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Salivary and rare head and neck cancers account for an estimated 3-10% of all head and neck cancers (roughly 2,500 diagnoses annually in the U.S.) The Center for Salivary and Rare Head and Neck Cancers is devoted to treating patients with these rare and
sometimes aggressive cancers arising from the head and neck.
Head and neck cancer treatment is already complex and necessitates expert involvement from head and neck surgeons, radiation oncologists, and medical oncologists. But tumors arising from the saliva glands and other rare entities require even more centralized expertise to deliver complex and highly personalized treatment approaches,
which often include targeted therapies.
Our Center focuses on treating the following head and neck cancer types:
The Center for Salivary and Rare Head and Neck Cancers offers several unique treatment and research opportunities largely unavailable elsewhere:
Many rare head and neck cancers lack standard or FDA-approved therapeutic options for managing advanced or metastatic disease; as a result, there is a crucial need for focused clinical trials. The Center for Salivary and Rare Head and Neck Cancers maintains
a broad clinical trial portfolio aimed at developing novel therapies for these diseases in collaboration with Dana-Farber's experimental therapeutics program,
the Center for Therapeutic Investigation (CTI).
Several translational laboratory investigators participate in our Center's research program – identifying novel therapeutic targets to integrate into the clinic. Our goal is to
centralize both clinical and translational research efforts to improve outcomes for patients with the most challenging and complex head and neck cancer diagnoses.
Deep and broad experience in rare head and neck cancers Centralized clinical and research expertise Active clinical trial portfolio Collaborative clinical and research approach driving therapeutic development
New Patient Appointments